One-year challenge data from preclinical study of ATI-1701 in lethal model of tularemia Nov. 22, 2021
New and known compounds targeting PTPRD may treat AD, addiction and restless legs syndrome Nov. 4, 2021
Aileron Therapeutics' ALRN-6924 shows preclinical activity against acute radiation injury Oct. 8, 2021
NIDA agrees to screen Initiator Pharma's preclinical assets for anti-addictive properties Sep. 20, 2021
RSS